A large retrospective study spanning two independent cohorts in Italy and Spain has uncovered a pattern that could reshape how clinicians think about biliary tract cancers: patients with gallbladder cancer were far more likely than patients with other biliary tract cancer subtypes to carry a prior history of breast cancer. The research, published in Volume 13 of the journal Oncoscience on September 17, 2026, was led by co-first authors Mara Persano and Margherita Rimini of the Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute Hospital in Milan, with Persano also affiliated with the Department of Biomedical Sciences at the University of Cagliari. The work represents one of the most systematic attempts to date to test whether the relationship between the two malignancies is specific to gallbladder cancer or merely a reflection of biliary tract cancer as a whole.
Biliary tract cancers are not a single disease but a heterogeneous family of tumors that includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer. These subtypes differ markedly in their epidemiology, clinical behavior and molecular underpinnings, which is precisely why the research team chose to disaggregate them. Their rationale was grounded in existing biology: several genetic alterations implicated in breast cancer, including HER2 amplification and the pathways connected to BRCA1 and BRCA2, have independently been identified in biliary tract cancers. If shared molecular machinery exists, the authors reasoned, then a history of breast cancer might cluster within one particular biliary subtype rather than across the spectrum. Gallbladder cancer emerged as the prime candidate for such a cluster.
The analysis enrolled 1,687 patients with biliary tract cancer across three centers. A training cohort of 204 patients was treated at San Raffaele in Milan between 2021 and 2023, while an independent validation cohort of 1,483 patients was drawn from the Vall d’Hebron Institute of Oncology in Spain and the Veneto Institute of Oncology in Italy between 2015 and 2023. This two-cohort architecture matters scientifically: any association that reproduces in a validation set is far less likely to be a statistical artifact of a single institution’s referral patterns or record-keeping quirks. The researchers then compared the prevalence of prior breast cancer between gallbladder cancer patients and those with other biliary subtypes within each cohort.
The results were striking in the training cohort. Among patients with gallbladder cancer, 25.7 percent had a documented history of breast cancer, compared with just 3.5 percent of patients with other biliary tract cancer subtypes, an odds ratio of 9.40. In the much larger validation cohort, the association persisted, though at a lower magnitude: previous breast cancer was identified in 5.1 percent of gallbladder cancer patients versus 2.4 percent of those with other subtypes, corresponding to an odds ratio of 2.18. The authors summarized the finding directly, noting that their study demonstrates a higher prevalence of prior breast cancer in patients with gallbladder cancer compared with patients with other biliary tract cancer subtypes across both the training and validation cohorts. The reproducibility across geographically distinct populations lends credibility to the signal, even as the discrepancy in effect size between the cohorts signals that the true magnitude remains uncertain.
Across the two cohorts combined, 58 patients had diagnoses of both breast cancer and biliary tract cancer. In 54 of those patients, or 93.1 percent, breast cancer came first, and the median interval between the two diagnoses was approximately seven years. That temporal sequence is intriguing but not conclusive. The authors are careful to point out that breast cancer is substantially more common than biliary tract cancer and generally occurs at a younger age, so a breast cancer diagnosis preceding a biliary one is, to some extent, exactly what base rates would predict. Sequence alone cannot establish a shared biological cause, and the study was not designed to test causation. What it does establish is that the co-occurrence is not randomly distributed across biliary subtypes, which is a genuinely novel observation.
The most tantalizing thread involves hormones. Among patients for whom breast cancer characteristics were available, most tumors were hormone receptor-positive and classified as luminal A or luminal B, the two subtypes driven by estrogen and progesterone signaling. This observation prompted the researchers to consider whether hormonal pathways might link the two cancers. There is precedent: estrogen and progesterone receptors have previously been described in gallbladder lesions, and estrogen-related signaling has been implicated experimentally in gallbladder cancer biology. The gallbladder, after all, is an organ exposed to circulating steroid hormones, and laboratory models have suggested that estrogen signaling can influence proliferation in gallbladder tissue. Still, the authors emphasize that the evidence for a hormonal connection remains limited and inconclusive, and the current study did not include the kind of receptor profiling in gallbladder tumors that would directly test the hypothesis.
The team also probed molecular similarities using genomic profiling, though only for a relatively small subgroup of gallbladder cancers. Alterations involving HER2, MDM2, CDKN2A, MTAP, ARID1A and CDKN2B occurred more frequently among patients with a history of breast cancer, while STK11 alterations were found exclusively among those without such a history. Several of these genes are familiar players in oncology: HER2 is a canonical breast cancer driver also actionable in a subset of biliary cancers, CDKN2A and CDKN2B govern cell-cycle checkpoints, and ARID1A is a chromatin-remodeling gene mutated across many tumor types. Yet none of the differences reached statistical significance, and the authors are explicit that the genomic findings should be considered exploratory rather than evidence of a shared molecular mechanism. The sample sizes simply were not sufficient to detect anything but very large effects.
A third hypothesis concerns inherited susceptibility. Germline alterations in genes such as BRCA1, BRCA2, BAP1 and STK11 are associated with hereditary cancer syndromes, and BRCA1 and BRCA2 are well established as drivers of inherited breast cancer risk. If a subset of patients carried germline variants predisposing to both malignancies, that could explain why breast cancer history clusters among gallbladder cancer patients. Unfortunately, germline testing was not available in the current study, so whether inherited genetic factors contribute to the observed association remains an open question. This gap is significant, because it means the study cannot distinguish between a shared environmental or hormonal exposure, common germline genetics, and the possibility that treatment or surveillance patterns for breast cancer survivors merely increase the likelihood that an incidental gallbladder tumor is detected.
The study’s limitations deserve emphasis. Its retrospective design could introduce inaccuracies in medical histories, and biological information was incomplete for some breast cancer cases. Genomic profiling was not performed uniformly across biliary tract cancer samples, the molecular analyses involved small numbers of patients, and germline testing was unavailable. The markedly different frequencies of prior breast cancer observed in the training and validation cohorts, 25.7 percent versus 5.1 percent among gallbladder cancer patients, underscore how much additional work is needed before the magnitude of the association can be pinned down. Referral patterns, screening intensity and differences in local practice could all contribute to that variation, and none can be excluded with retrospective data.
Nevertheless, the core finding is reproducible and clinically provocative: a history of breast cancer is overrepresented among gallbladder cancer patients relative to other biliary tract cancer patients in two independent cohorts. Hormonal signaling, inherited susceptibility and overlapping molecular pathways are all plausible explanations, but none has yet been established. The authors argue that future studies should invert the analytical direction, starting with breast cancer populations and investigating their subsequent risk of biliary tract cancer, particularly gallbladder cancer. Such forward-looking cohort designs could determine whether breast cancer survivors genuinely face an elevated risk and whether the association might eventually inform risk stratification or long-term surveillance strategies. For now, the study stands as a well-powered observational signal, a biological puzzle with three candidate mechanisms, and a clear roadmap for the prospective research that must follow before any change to clinical practice could be justified.
Subject of Research: Association between prior breast cancer and gallbladder cancer prevalence among biliary tract cancer subtypes
Article Title: Prior breast cancer linked to higher prevalence of gallbladder cancer among biliary tract cancers
Article References: Prior breast cancer linked to higher prevalence of gallbladder cancer among biliary tract cancers. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: gallbladder cancer, breast cancer, biliary tract cancer, cholangiocarcinoma, hormone receptors, HER2, BRCA1, BRCA2, genomic profiling, retrospective cohort study, cancer epidemiology, Oncoscience
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (October 3, 2026). Breast Cancer History Emerges as Striking Signal in Gallbladder Cancer Patients. Scienmag. https://scienmag.com/breast-cancer-history-emerges-as-striking-signal-in-gallbladder-cancer-patients/
Nathaniel Bowman. “Breast Cancer History Emerges as Striking Signal in Gallbladder Cancer Patients.” Scienmag, 3 October 2026, https://scienmag.com/breast-cancer-history-emerges-as-striking-signal-in-gallbladder-cancer-patients/. Accessed 3 October 2026.
Nathaniel Bowman. “Breast Cancer History Emerges as Striking Signal in Gallbladder Cancer Patients.” Scienmag. October 3, 2026. https://scienmag.com/breast-cancer-history-emerges-as-striking-signal-in-gallbladder-cancer-patients/
Copy citation Download RIS
Tags: advances in understanding biliarybiliary tract cancerbiliary tract cancer subtypesBRCA1BRCA2breast cancerbreast cancer as a risk factor for gallbladder cancerBreast cancer history and gallbladder cancercancer epidemiologycholangiocarcinomaclinical implications of cancer comorbiditycross-cohort cancer pattern researchepidemiology of biliary tract cancersGallbladder cancergenetic alterations linking breast and biliary cancersgenomic profilingHER2hormone receptorsimpact of prior breast cancer on biliary tract cancer developmentmolecular differences in cholangiocarcinomaOncoscienceretrospective cancer cohort studiesretrospective cohort studysystematic analysis of biliary tract cancers
